Relapsed mixed lineage leukemia
Showing 1 - 25 of >10,000
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage Trial in Houston (Clofarabine,
Recruiting
- Acute Bilineal Leukemia
- +7 more
- Clofarabine
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute Trial in Japan, United States (DSP-5336)
Recruiting
- Leukemia, Myeloid, Acute
- Leukemia, Lymphocytic, Acute
-
Houston, Texas
- +5 more
May 31, 2022
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Not yet recruiting
- Recurrent Acute Leukemia of Ambiguous Lineage
- +5 more
- Biospecimen Collection
- +12 more
- (no location specified)
Mar 8, 2023
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation Trial (Ziftomenib, Venetoclax,
Not yet recruiting
- Acute Myeloid Leukemia
- +10 more
- Ziftomenib
- +4 more
- (no location specified)
Feb 17, 2023
ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)
Not yet recruiting
- ALL, Childhood B-Cell
- +2 more
- Tafasitamab
- (no location specified)
Nov 25, 2022
Leukemia, T Cell Trial in Beijing (CD7 CART)
Recruiting
- Leukemia, T Cell
- CD7 CART
-
Beijing, Hebei, ChinaHe bei Yan da Lu dao pei Hospital
May 24, 2022
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19
Recruiting
- Lymphoblastic Leukemia
- +5 more
- Anti-CD19 CAR T-cells
-
Singapore, Singapore
- +1 more
Dec 4, 2022
Leukemia Trial in Houston (Cyclophosphamide, Vincristine, Blinatumomab)
Not yet recruiting
- Leukemia
- Cyclophosphamide
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Dec 23, 2022
Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase
Recruiting
- Lymphoblastic Leukemia
- +4 more
- Phase I
- Phase II
-
Singapore, SingaporeKK Women's and Children's hospital
Jun 20, 2022
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))
Recruiting
- Mixed Phenotype Acute Leukemia (MPAL)
- Measurable Residual Disease (MRD)
- BLINCYTO (Blinatumomab)
-
Baltimore, MarylandGreenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in
Completed
- Recurrent Acute Leukemia of Ambiguous Lineage
- +5 more
- Chemosensitivity Assay
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 29, 2022
B-Cell Acute Lymphoblastic Leukemia, Adult Trial in La Jolla, Orange, San Francisco (blinatumomab, pembrolizumab)
Terminated
- B-Cell Acute Lymphoblastic Leukemia, Adult
-
La Jolla, California
- +2 more
Apr 26, 2022
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (CAR
Recruiting
- Lymphoblastic Leukemia, Acute, Childhood
- +6 more
- CAR T-cell therapy
-
Singapore, SingaporeAllen Yeoh Eng Juh
Sep 7, 2021
Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia Trial
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- +7 more
- Anti-CD123 ADC IMGN632
- +7 more
- (no location specified)
Dec 28, 2022
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia Trial in Seattle (Cladribine, Cytarabine,
Recruiting
- Acute Biphenotypic Leukemia
- +11 more
- Cladribine
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 18, 2022
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (CAR
Recruiting
- Lymphoblastic Leukemia, Acute, Childhood
- +5 more
- CAR T-cell therapy
-
Singapore, SingaporeAllen Yeoh Eng Juh
Sep 7, 2021
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia Trial in Kansas City, Cincinnati
Recruiting
- Relapsed/Refractory Leukemias
- +4 more
- SNDX-5613
- +2 more
-
Kansas City, Missouri
- +1 more
Jul 18, 2022
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in
Suspended
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Blinatumomab
- +2 more
-
New Haven, Connecticut
- +6 more
Jul 9, 2022
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 13, 2022
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid
Recruiting
- Acute Lymphoblastic Leukemia in Remission
- +11 more
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 24, 2022
Acute Lymphoblastic Leukemia Trial in United States (ADCT-402)
Terminated
- Acute Lymphoblastic Leukemia
-
La Jolla, California
- +9 more
Apr 27, 2021
Acute Myelogenous Leukemia, MDS, Mixed Phenotype Acute Leukemia Trial (Fludarabine, Cytarabine, Uproleselan)
Not yet recruiting
- Acute Myelogenous Leukemia
- +2 more
- Fludarabine
- +2 more
- (no location specified)
Mar 3, 2022